Mr. Hovard, who will serve as the Company’s first independent Director, brings more than 20 years of leadership in the medical device and urology industry. Over the last 20 years, Mr. Hovard has held multiple leadership roles at subsidiaries of Coloplast, a publicly-traded global medical device company. Most recently, he served as the President of Interventional Urology from 2011 to 2019.
by eazee-designstudio
Dr. Murphy joins the company with over twenty years of experience in Class I, II, and III medical devices and implantables and has been instrumental in bringing numerous new devices to commercialization. As a member of GTX’ leadership team, Dr. Murphy will be responsible for leading and executing the company’s technology strategy and advancing its neuromodulation product portfolio, which is designed to improve the functional recovery of people with spinal cord injuries (SCI).
Dr. Dukes has amassed over 20 years in leadership roles at large pharmaceutical and biotechnology companies. As Themis transitions towards rapidly ramping up the development of a coronavirus vaccine candidate towards the clinic in response to the global pandemic and being prepared to supply the initial stockpiles of its vaccine, Dr. Dukes’ background will further enhance the range of experience on the Company’s Board.
STipe Therapeutics announced the appointment of seasoned industry experts: “Both Natalie and Richard are highly experienced industry executives who bring a wealth of international drug development and approval expertise to STipe,” said Dr Claus Elsborg Olesen (CEO). “We are developing novel cancer therapies and I look forward to drawing on their extensive experience as we prepare for the selection of a lead candidate for clinical development.”
Wellington Partners today announced a seed investment into newly founded SIRS Therapeutics, Munich, Germany. With the investment, SIRS has secured the joint ownership with Austrian F4 Pharma of all rights on FX06, a fibrin-derived peptide for treatment of patients with acute respiratory distress syndrome (ARDS) and systemic inflammatory response syndrome (SIRS), including patients with underlying COVID-19 infection.
